Merck & Co Inc

Quantli Newsdesk

· 18 hours ago

Merck's collaboration with Moderna on a personalized cancer vaccine achieved positive results in a late-stage melanoma trial, demonstrating reduced recurrence rates. The breakthrough validates Merck's oncology strategy and strengthens its partnership with Moderna in the emerging field of mRNA-based cancer therapies.

Quantli Newsdesk

· 2 days ago

Merck and Moderna announced that their personalized mRNA cancer vaccine, intismeran, combined with Merck's Keytruda, met key goals in a Phase 3 trial for high-risk melanoma patients. The treatment reduced cancer recurrence and prevented tumors from spreading compared to Keytruda alone. This marks the first successful late-stage trial for an mRNA cancer vaccine, validating the technology beyond COVID-19.

Quantli Newsdesk

· 2 months ago

Abu Dhabi's Department of Health and Biocom California formed a strategic partnership to connect California's life sciences ecosystem with Abu Dhabi's HELM Cluster. The collaboration aims to accelerate healthcare innovation by linking over 1,800 life sciences organizations with Abu Dhabi's living lab model. For Merck, this creates potential opportunities to access new research partnerships, validation environments, and regional market entry points in the Middle East.

Quantli Newsdesk

· 3 months ago

Merck and Moderna presented five-year follow-up data from their phase 2b trial showing that intismeran autogene, a personalized mRNA cancer vaccine combined with KEYTRUDA, reduced the risk of melanoma recurrence or death by 49% compared to KEYTRUDA alone in high-risk patients. The therapy has now advanced to phase 3 trials and demonstrated a manageable safety profile with no serious vaccine-related adverse events.

Quantli Newsdesk

· 3 months ago

Merck reported first-quarter sales of $16.29 billion, surpassing expectations on 12% growth from Keytruda. The company raised its full-year earnings guidance while navigating the 2028 patent expiration for its flagship cancer drug, which accounts for over half of pharmaceutical sales.

10-K

Quantli Newsdesk

· 4 months ago

Merck delivered modest 1% revenue growth to $65.0 billion in 2025, with Keytruda representing 49% of total sales and growing 7%, while Gardasil declined 39% due to a China shipment pause. Non-GAAP EPS rose 17% to $8.98 as the company advanced restructuring programs targeting $3.0 billion in annual cost savings by 2027.